BT Pharma appoints Thierry Hercend president of supervisory board
This article was originally published in Scrip
Executive Summary
BT Pharma, a French biopharmaceutical company developing innovative immunotherapies to treat diseases and cancer caused by the human papillomavirus, has appointed Professor Thierry Hercend president of its supervisory board. Professor Hercend has more than 30 years' academic and pharmaceutical experience in various therapeutic areas, including oncology and inflammatory diseases. From 2002-05, he was vice-president of oncology research of Aventis. He has also worked at Vertex Pharmaceuticals, LFB (Laboratoire Français du Fractionnement et des Biotechnologies) and Roussel Uclaf.